ENDRA Life Sciences- Warrants (12/05/2022) EBIT

The latest EBIT for NDRAW is $-1.6M as of June 2026. That compares with $-5.7M in the prior-year period — up 72.2% year over year. That is below the Technology sector average of $14T. Investors often review this figure alongside ENDRA Life Sciences- Warrants (12/05/2022)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, NDRAW's EBIT moved from $-5.7M to $-1.6M — a 72.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ENDRA Life Sciences- Warrants (12/05/2022)'s operating scale or balance-sheet position.

Against Technology companies, NDRAW currently prints $-1.6M for EBIT, while the sector average sits near $14T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at ENDRA Life Sciences- Warrants (12/05/2022)'s growth, margins, and balance sheet.

A EBIT figure of $-1.6M for NDRAW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Technology average is about $14T. Explore the charts below for those layers of context.

After noting NDRAW's EBIT ($-1.6M), review year-over-year change from $-5.7M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.